130.71
price down icon0.46%   -0.61
pre-market  시장 영업 전:  129.08   -1.63   -1.25%
loading
전일 마감가:
$131.32
열려 있는:
$132.37
하루 거래량:
1.76M
Relative Volume:
1.20
시가총액:
$19.04B
수익:
$9.61B
순이익/손실:
$1.62B
주가수익비율:
11.81
EPS:
11.07
순현금흐름:
$1.77B
1주 성능:
-6.86%
1개월 성능:
-7.76%
6개월 성능:
-29.26%
1년 성능:
-36.67%
1일 변동 폭
Value
$130.05
$133.77
1주일 범위
Value
$128.75
$141.25
52주 변동 폭
Value
$128.51
$238.00

Biogen Inc Stock (BIIB) Company Profile

Name
명칭
Biogen Inc
Name
전화
(781) 464-2000
Name
주소
225 BINNEY STREET, CAMBRIDGE, MA
Name
직원
7,570
Name
트위터
@biogen
Name
다음 수익 날짜
2024-10-30
Name
최신 SEC 제출 서류
Name
BIIB's Discussions on Twitter

BIIB을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
BIIB
Biogen Inc
130.71 19.04B 9.61B 1.62B 1.77B 11.07
Drug Manufacturers - General icon
LLY
Lilly Eli Co
789.09 708.74B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
ABBV
Abbvie Inc
201.64 356.70B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
JNJ
Johnson Johnson
159.82 344.63B 88.82B 14.07B 18.06B 5.79
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
67.10 297.86B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
112.26 221.72B 51.72B 11.94B 13.81B 5.88

Biogen Inc Stock (BIIB) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-11 개시 Bernstein Mkt Perform
2025-01-02 다운그레이드 Piper Sandler Overweight → Neutral
2024-12-20 다운그레이드 BMO Capital Markets Outperform → Market Perform
2024-12-16 다운그레이드 Stifel Buy → Hold
2024-12-10 재개 BofA Securities Neutral
2024-12-09 다운그레이드 Jefferies Buy → Hold
2024-11-18 다운그레이드 Needham Buy → Hold
2024-11-15 개시 Wolfe Research Peer Perform
2024-11-14 개시 Citigroup Neutral
2024-10-31 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2024-10-10 재개 Raymond James Mkt Perform
2024-02-14 재확인 Needham Buy
2024-02-14 다운그레이드 Wells Fargo Overweight → Equal Weight
2024-01-24 다운그레이드 UBS Buy → Neutral
2023-12-20 재개 Cantor Fitzgerald Overweight
2023-12-07 업그레이드 Raymond James Mkt Perform → Outperform
2023-09-06 개시 HSBC Securities Buy
2023-07-27 개시 Scotiabank Sector Outperform
2023-07-24 재확인 UBS Buy
2023-05-01 업그레이드 Guggenheim Neutral → Buy
2023-04-17 업그레이드 Piper Sandler Neutral → Overweight
2022-10-26 업그레이드 Goldman Neutral → Buy
2022-10-13 업그레이드 Stifel Hold → Buy
2022-10-07 업그레이드 Argus Hold → Buy
2022-09-28 업그레이드 BMO Capital Markets Market Perform → Outperform
2022-09-28 업그레이드 Mizuho Neutral → Buy
2022-09-28 업그레이드 Robert W. Baird Neutral → Outperform
2022-04-18 업그레이드 Wells Fargo Equal Weight → Overweight
2022-03-08 다운그레이드 Stifel Buy → Hold
2022-03-03 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2022-02-04 다운그레이드 BMO Capital Markets Outperform → Market Perform
2022-02-04 재확인 Barclays Equal Weight
2022-02-04 재확인 BofA Securities Neutral
2022-02-04 재확인 Cowen Outperform
2022-02-04 재확인 Morgan Stanley Overweight
2022-02-04 재확인 Needham Buy
2022-02-04 재확인 Oppenheimer Outperform
2022-02-04 재확인 RBC Capital Mkts Sector Perform
2022-02-04 재확인 Robert W. Baird Neutral
2022-02-04 재확인 Wedbush Neutral
2022-02-04 재확인 Wells Fargo Equal Weight
2022-02-04 재확인 Wolfe Research Peer Perform
2022-01-13 다운그레이드 Guggenheim Buy → Neutral
2022-01-12 다운그레이드 Piper Sandler Overweight → Neutral
2021-12-10 재개 Raymond James Mkt Perform
2021-12-09 재개 Wells Fargo Equal Weight
2021-12-06 개시 Goldman Neutral
2021-11-19 개시 BMO Capital Markets Outperform
2021-09-23 개시 Needham Buy
2021-06-18 업그레이드 Piper Sandler Neutral → Overweight
2021-06-14 재확인 Truist Buy
2021-06-11 업그레이드 Bernstein Mkt Perform → Outperform
2021-06-10 업그레이드 UBS Neutral → Buy
2021-06-08 업그레이드 Atlantic Equities Underweight → Neutral
2021-06-08 재확인 Barclays Equal Weight
2021-06-08 업그레이드 Citigroup Sell → Neutral
2021-06-08 재확인 H.C. Wainwright Buy
2021-06-08 재확인 Jefferies Buy
2021-06-08 재확인 Morgan Stanley Overweight
2021-06-08 재확인 RBC Capital Mkts Sector Perform
2021-06-08 업그레이드 Robert W. Baird Underperform → Neutral
2021-06-08 재확인 Stifel Buy
2021-06-08 업그레이드 William Blair Mkt Perform → Outperform
2021-06-07 업그레이드 BofA Securities Underperform → Neutral
2021-06-07 업그레이드 Cowen Market Perform → Outperform
2021-06-07 업그레이드 Raymond James Underperform → Mkt Perform
2021-02-05 다운그레이드 DZ Bank Buy → Hold
2021-01-29 업그레이드 Stifel Hold → Buy
2020-11-10 업그레이드 DZ Bank Hold → Buy
2020-11-09 다운그레이드 Atlantic Equities Neutral → Underweight
2020-11-09 다운그레이드 BofA Securities Neutral → Underperform
2020-11-09 다운그레이드 Cowen Outperform → Market Perform
2020-11-09 재확인 H.C. Wainwright Buy
2020-11-04 업그레이드 BofA Securities Underperform → Neutral
2020-11-04 업그레이드 Jefferies Hold → Buy
2020-11-04 업그레이드 Wells Fargo Equal Weight → Overweight
2020-10-28 개시 UBS Neutral
2020-07-27 업그레이드 Morgan Stanley Underweight → Overweight
2020-06-22 다운그레이드 Barclays Overweight → Equal Weight
2020-06-22 재확인 RBC Capital Mkts Sector Perform
2020-06-09 다운그레이드 Bernstein Outperform → Mkt Perform
2020-04-23 다운그레이드 Citigroup Neutral → Sell
2020-04-23 다운그레이드 Raymond James Mkt Perform → Underperform
2020-03-31 개시 Wolfe Research Peer Perform
2020-02-27 개시 Barclays Overweight
2020-01-27 업그레이드 Canaccord Genuity Hold → Buy
2019-12-13 업그레이드 Credit Suisse Underperform → Neutral
2019-12-02 다운그레이드 Robert W. Baird Neutral → Underperform
모두보기

Biogen Inc 주식(BIIB)의 최신 뉴스

pulisher
06:08 AM

United Bank Sells 2,213 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

06:08 AM
pulisher
05:23 AM

Biogen Inc. (NASDAQ:BIIB) Stock Position Lowered by Groupama Asset Managment - MarketBeat

05:23 AM
pulisher
05:07 AM

Biogen Inc. (NASDAQ:BIIB) Shares Sold by Pictet Asset Management Holding SA - MarketBeat

05:07 AM
pulisher
05:07 AM

Biogen Inc. (NASDAQ:BIIB) Shares Purchased by B. Metzler seel. Sohn & Co. AG - MarketBeat

05:07 AM
pulisher
04:39 AM

Korea Investment CORP Reduces Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

04:39 AM
pulisher
03:08 AM

DnB Asset Management AS Has $7.26 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

03:08 AM
pulisher
02:08 AM

Saratoga Research & Investment Management Sells 149,272 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

02:08 AM
pulisher
01:08 AM

Norges Bank Makes New $355.57 Million Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

01:08 AM
pulisher
01:07 AM

Mitsubishi UFJ Asset Management Co. Ltd. Increases Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

01:07 AM
pulisher
12:07 PM

Level Four Advisory Services LLC Has $1.14 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

12:07 PM
pulisher
Apr 03, 2025

Biogen Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationBIIB - ACCESS Newswire

Apr 03, 2025
pulisher
Apr 03, 2025

Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your RightsBIIB - ACCESS Newswire

Apr 03, 2025
pulisher
Apr 03, 2025

Biogen (NasdaqGS:BIIB) Gets US FDA Fast Track For Alzheimer's Despite US$8M Settlement - simplywall.st

Apr 03, 2025
pulisher
Apr 03, 2025

May 23rd Options Now Available For Biogen (BIIB) - Nasdaq

Apr 03, 2025
pulisher
Apr 03, 2025

BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag - Nasdaq

Apr 03, 2025
pulisher
Apr 03, 2025

RBC Capital cuts Biogen stock price target to $221 - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

California Public Employees Retirement System Has $60.84 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Apr 03, 2025
pulisher
Apr 03, 2025

Biogen Inc. (NASDAQ:BIIB) Shares Sold by Sei Investments Co. - MarketBeat

Apr 03, 2025
pulisher
Apr 02, 2025

Beutel Goodman & Co Ltd. Purchases 2,323 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Biogen (NASDAQ:BIIB) Shares Acquired Rep. Robert Bresnahan, Jr. - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Biogen (BIIB) Gains FDA Fast Track for Alzheimer's Therapy - GuruFocus

Apr 02, 2025
pulisher
Apr 02, 2025

Biogen’s tau targeting Alzheimer’s disease therapy gets FDA Fast Track status - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Leqembi’s EU review drags on; Sanofi gets a new development head - BioPharma Dive

Apr 02, 2025
pulisher
Apr 02, 2025

Organon acquires Actemra biosimilar’s US rights from Biogen - Yahoo Finance

Apr 02, 2025
pulisher
Apr 02, 2025

Biogen’s BIIB080 gains FDA fast track for Alzheimer’s By Investing.com - Investing.com Australia

Apr 02, 2025
pulisher
Apr 02, 2025

Biogen’s BIIB080 gains FDA fast track for Alzheimer’s - Investing.com India

Apr 02, 2025
pulisher
Apr 02, 2025

Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease - Biogen

Apr 02, 2025
pulisher
Apr 02, 2025

Breakthrough: Biogen's First-of-its-Kind Alzheimer's Drug Gains FDA Fast Track Status - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition - insights.citeline.com

Apr 02, 2025
pulisher
Apr 02, 2025

Headlands Technologies LLC Buys 27,129 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

4,298 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Allstate Corp - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Biogen Inc. (NASDAQ:BIIB) Stock Holdings Decreased by Wellington Management Group LLP - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Biogen Inc. (NASDAQ:BIIB) Shares Sold by American Century Companies Inc. - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Immunomodulators Market Set to Witness Significant Growth - openPR.com

Apr 02, 2025
pulisher
Apr 01, 2025

Organon Expands Biosimilar Portfolio With Tofidence Acquisition - Managed Healthcare Executive

Apr 01, 2025
pulisher
Apr 01, 2025

Multiple Sclerosis Pipeline 2025: Key Companies, MOA, ROA, - openPR.com

Apr 01, 2025
pulisher
Apr 01, 2025

Biogen Inc. stock outperforms competitors despite losses on the day - MSN

Apr 01, 2025
pulisher
Apr 01, 2025

Biogen Says Investigational Alzheimer's Drug Receives FDA Fast Track Designation - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

FDA-Approved Biosimilars Market: A Complete List & Latest - openPR.com

Apr 01, 2025
pulisher
Apr 01, 2025

Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra - Seeking Alpha

Apr 01, 2025
pulisher
Apr 01, 2025

Organon acquires US rights to arthritis biosimilar TOFIDENCE - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Organon acquires US rights to arthritis biosimilar TOFIDENCE By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Organon Claims US Market Leadership with Groundbreaking Tocilizumab Biosimilar Deal - Stock Titan

Apr 01, 2025
pulisher
Apr 01, 2025

EC refers lecanemab decision to Appeal Committee - The Pharma Letter

Apr 01, 2025
pulisher
Apr 01, 2025

Biogen (NASDAQ:BIIB) sheds US$697m, company earnings and investor returns have been trending downwards for past five years - Yahoo Finance

Apr 01, 2025
pulisher
Apr 01, 2025

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission - Biogen

Apr 01, 2025
pulisher
Mar 31, 2025

Thrivent Financial for Lutherans Has $2.42 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 31, 2025
pulisher
Mar 31, 2025

The US Approved an Alzheimer's Drug. Seven Patients Subsequently Died - Bloomberg

Mar 31, 2025
pulisher
Mar 31, 2025

The US approved an Alzheimer’s drug. Seven patients subsequently died. - The Boston Globe

Mar 31, 2025
pulisher
Mar 31, 2025

Mitsubishi UFJ Trust & Banking Corp Increases Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat

Mar 31, 2025

Biogen Inc (BIIB) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general SNY
$54.62
price up icon 1.24%
drug_manufacturers_general PFE
$24.29
price down icon 1.66%
$112.39
price up icon 0.45%
$309.85
price up icon 1.36%
drug_manufacturers_general MRK
$86.39
price down icon 0.24%
drug_manufacturers_general NVS
$112.26
price up icon 1.35%
자본화:     |  볼륨(24시간):